{"schema_version":1,"research_id":"eoa_inverse_innovation_exp03_external48_20260801","source_assessment_id":"eoa_inverse_innovation_exp03_opportunity320_20260801","cell_id":"deadweight_loss_reduction__medicine_healthcare","selection_stratum":"DEPLOYABLE_PRIORITY","search_queries":["site:cms.gov prior authorization continuity ongoing course treatment 2024 final rule prior approval","automatic renewal prior authorization stable patients maintenance therapy payer policy","prior authorization medication gaps primary study treatment interruption stable therapy","site:ama-assn.org prior authorization survey treatment abandonment physician burden 2024","\"These prescriptions will be automatically extended per the PA policy\"","payer \"automatic renewal\" prior authorization medication","primary study prior authorization renewal treatment interruption medication gaps specialty therapy","CMS-0057-F estimated cost payer implementation prior authorization API compliance cost"],"sources":[{"source_id":"S1","title":"Prior Authorization and Association With Delayed or Discontinued Prescription Fills","publisher":"Journal of Clinical Oncology / National Library of Medicine","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10927330/","source_class":"PRIMARY_RESEARCH","publication_date":"2023-12-12","accessed_at":"2026-08-02","claims_supported":["A quasi-experimental study examined Medicare Part D beneficiaries regularly filling 11 oral anticancer drugs when plans introduced prior authorization.","Introducing prior authorization on an established regimen was associated with 9.7 additional days to the next fill and adjusted odds of discontinuation within 120 days of 7.1 relative to plans without the change.","The study supports disruption from imposing authorization on established therapy, but does not isolate routine authorization expiration or renewal."]},{"source_id":"S2","title":"The Patient Experience of Prior Authorization for Cancer Care","publisher":"JAMA Network Open","url":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810824","source_class":"PRIMARY_RESEARCH","publication_date":"2023-10-18","accessed_at":"2026-08-02","claims_supported":["In a convenience sample of 178 patients with cancer who had prior-authorization experience, 69% reported delayed care and 22% reported not receiving recommended care because of delays or denials.","Twenty percent reported spending at least 11 hours addressing prior-authorization issues.","The sample included patients receiving hormonal and other maintenance treatment, but selection and self-report limit generalizability and do not establish renewal-specific effects."]},{"source_id":"S3","title":"2025 AMA Prior Authorization Physician Survey","publisher":"American Medical Association","url":"https://www.ama-assn.org/system/files/2021-04/prior-authorization-survey.pdf","source_class":"OFFICIAL_ORGANIZATION_DATA","publication_date":"2026-05-13","accessed_at":"2026-08-02","claims_supported":["The survey reports approximately 40 prior authorizations and 13 physician-and-staff hours per physician each week.","It documents broad physician-reported administrative burden, delays and concern about patient harm.","The evidence reflects physician reports rather than adjudication-linked causal measurement."]},{"source_id":"S4","title":"Medi-Cal Rx Frequently Asked Questions","publisher":"California Department of Health Care Services","url":"https://www.dhcs.ca.gov/providers-partners/pharmacy-benefits-division-and-vision-care-program/medi-cal-rx-frequently-asked-questions/","source_class":"GOVERNMENT_OR_REGULATOR","publication_date":"n.d.","accessed_at":"2026-08-02","claims_supported":["DHCS states that it enabled extended-duration prior authorizations of up to five years for certain chronic-condition maintenance medications and automatically extended qualified prescriptions.","The program also uses auto-adjudication and retains clinical drug-coverage rules, demonstrating payer authority and technical feasibility for selective automation.","The page does not report a controlled evaluation of continuity, safety, equity, utilization or fiscal outcomes from automatic extension."]},{"source_id":"S5","title":"Extended Duration Prior Authorizations for Maintenance Medications","publisher":"California Department of Health Care Services, Medi-Cal Rx","url":"https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/provider/bulletins/2023.03_A_Extended_Duration_PAs_Maintenance_Medications.pdf","source_class":"GOVERNMENT_OR_REGULATOR","publication_date":"2023-03-22","accessed_at":"2026-08-02","claims_supported":["The archived implementation bulletin states that eligible maintenance prescriptions with an approved authorization or paid-claims history in a 15-month lookback were automatically extended without provider action.","The policy covered selected maintenance drug classes while retaining quantity, age, diagnosis and other clinical edits.","This is a close implemented analogue, although the bulletin is archived and does not supply outcome evaluation or rollback thresholds."]},{"source_id":"S6","title":"Carrier Letter 2024-05: Consolidated Pharmacy Benefits Guidance for the FEHB Program","publisher":"U.S. Office of Personnel Management","url":"https://www.opm.gov/healthcare-insurance/carriers/fehb/2024/2024-05.pdf","source_class":"OFFICIAL_GUIDANCE","publication_date":"2024-02-12","accessed_at":"2026-08-02","claims_supported":["OPM required FEHB carriers to review expiring maintenance-medication authorizations and notify members at least 45 days before expiration.","OPM encouraged automatic renewal when a member has a chronic condition, regularly fills the medication and the authorization is not imposed for safety reasons.","The guidance closely matches risk-tiered renewal but does not establish that every carrier implemented it or that outcomes were evaluated."]},{"source_id":"S7","title":"2024 Medicare Advantage and Part D Final Rule (CMS-4201-F)","publisher":"Centers for Medicare & Medicaid Services","url":"https://www.cms.gov/newsroom/fact-sheets/2024-medicare-advantage-and-part-d-final-rule-cms-4201-f","source_class":"GOVERNMENT_OR_REGULATOR","publication_date":"2023-04-05","accessed_at":"2026-08-02","claims_supported":["CMS requires Medicare Advantage coordinated-care plans to make an authorization valid for as long as medically reasonable and necessary for a course of treatment.","CMS also requires a 90-day transition period for an active course of treatment after switching plans and annual utilization-management committee review.","These rules demonstrate regulatory support for continuity and recurring payer governance but are not a drug-specific automatic-renewal algorithm."]},{"source_id":"S8","title":"CMS Interoperability and Prior Authorization Final Rule CMS-0057-F","publisher":"Centers for Medicare & Medicaid Services","url":"https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f","source_class":"GOVERNMENT_OR_REGULATOR","publication_date":"2024-01-17","accessed_at":"2026-08-02","claims_supported":["CMS requires affected payers to implement standardized prior-authorization process improvements and APIs for covered medical items and services.","The rule's prior-authorization API requirements exclude drugs, so medication auto-renewal still depends on pharmacy-benefit and payer-specific systems.","Electronic prior-authorization infrastructure is an adjacent transaction-speed intervention rather than an exemption from full renewal review."]}],"problem_evidence":{"support":"MODERATE","rationale":"S1 directly shows that placing a new authorization requirement on patients already filling stable oral anticancer regimens can delay refills and increase discontinuation. S2 and S3 independently document patient and practice burden. However, none isolates recurring expiration of an unchanged authorization from affordability, stock, adherence, prescribing delay or other causes, so the candidate's exact prevalence and effect size remain unverified.","source_ids":["S1","S2","S3"]},"stakeholder_evidence":{"support":"STRONG","rationale":"Physicians report substantial workload and patient disruption, while DHCS, OPM and CMS have adopted or promoted continuity-oriented authorization reforms. This demonstrates both expressed stakeholder demand and action by credible authorizers, although payer willingness may vary by therapy and financial risk.","source_ids":["S3","S4","S6","S7"]},"prior_art":{"proximity":"ESTABLISHED_PRACTICE","closest_analogues":[{"name":"Medi-Cal Rx extended-duration maintenance-medication prior authorizations","similarity":"Selected maintenance prescriptions with prior approval or recent paid-claims history were automatically extended, while quantity, age, diagnosis and other clinical edits remained applicable. This implements the candidate's central selective-renewal mechanism.","remaining_difference":"The candidate additionally proposes an explicitly preregistered comparison, broader material-change triggers, protected-outcome monitoring and rollback thresholds. The Medi-Cal documents do not establish those evaluation features or their incremental value.","source_ids":["S4","S5"]},{"name":"OPM chronic-maintenance automatic-renewal guidance","similarity":"OPM encouraged automatic renewal when chronic-condition status, regular fills and absence of a safety-based authorization indicate lower risk, closely matching stability criteria plus a safety exception.","remaining_difference":"This is guidance rather than evidence that all FEHB carriers implemented one uniform trigger system; the candidate would need to operationalize and validate additional clinical, misuse, eligibility and nonresponse triggers.","source_ids":["S6"]},{"name":"CMS continuity-of-care authorization duration requirements","similarity":"CMS requires authorization to remain valid for a medically necessary course of treatment and protects active treatment during plan transitions, reducing repeat authorization barriers for unchanged care.","remaining_difference":"The rule is not a pharmacy-specific, claims-triggered auto-renewal policy and does not test a risk-classification algorithm against ordinary renewal or electronic prior authorization.","source_ids":["S7","S8"]}],"distinctive_claim_remaining":"No distinctive core mechanism remains: selective automatic extension of maintenance-medication authorizations with retained safety or clinical edits is documented practice. A narrower testable contribution could be whether an operationalized material-change trigger set outperforms existing extended-duration policies and ordinary renewal on authorization-attributable gaps and workload while remaining within prespecified missed-review, safety, equity, utilization and fiscal margins.","confidence":"HIGH"},"implementation_evidence":{"support":"STRONG","rationale":"Medi-Cal Rx documents operational automatic extension using authorization and paid-claims history, and OPM specifies implementable chronic-condition, refill-history and safety criteria. CMS requirements also establish payer governance and continuity authority. Evidence is still missing for the candidate's expanded trigger sensitivity, comparative outcomes, monitoring thresholds and rollback performance.","source_ids":["S4","S5","S6","S7","S8"]},"scores":{"meaningful_impact":{"score":4,"rationale":"Primary research links authorization imposed on established oral anticancer therapy to substantial refill delay and discontinuation, while patient and physician surveys document burden. Renewal-specific population impact remains unmeasured.","source_ids":["S1","S2","S3"]},"stakeholder_pull":{"score":4,"rationale":"Clinician demand is strong and several public authorities have acted on treatment continuity or automatic renewal. Therapy-specific payer acceptance and patient demand for this exact design are not quantified.","source_ids":["S3","S4","S6","S7"]},"incremental_advantage":{"score":2,"rationale":"Exempting eligible stable cases could outperform electronic processing that only accelerates review, but the same selective-extension mechanism already exists. No evidence shows the proposed additional triggers outperform Medi-Cal's extended-duration approach or OPM's criteria.","source_ids":["S4","S5","S6","S8"]},"distinctiveness_plausibility":{"score":1,"rationale":"The core composition substantially collides with implemented Medi-Cal policy and OPM guidance. Only the particular validated trigger set and comparative monitoring protocol could remain distinctive, and neither is operationalized.","source_ids":["S4","S5","S6"]},"technical_implementability":{"score":4,"rationale":"Official documentation demonstrates use of prior approvals, paid-claims history, eligibility lists and clinical edits for automatic extension. More complex clinical-change detection would require additional data integration and validation.","source_ids":["S4","S5","S6","S8"]},"adoption_authority_feasibility":{"score":4,"rationale":"DHCS implemented the mechanism, OPM directs FEHB carrier practices and CMS regulates authorization duration and governance. A chosen payer still must confirm pharmacy-benefit contracts, clinical governance and applicable appeal obligations.","source_ids":["S4","S6","S7"]},"evidence_readiness":{"score":3,"rationale":"Claims and authorization histories support quasi-experimental analysis, as S1 demonstrates, and implemented policies provide exposed cohorts. Clinical-review yield, exception-trigger sensitivity, staff effort and protected outcomes require linkage and manual validation.","source_ids":["S1","S4","S5"]},"safety_net_benefit":{"score":3,"rationale":"The design retains safety and clinical exceptions, consistent with OPM and Medi-Cal approaches. No source validates sensitivity for contraindications, deterioration, misuse, nonresponse or eligibility changes, so protective benefit remains uncertain.","source_ids":["S5","S6"]},"scalability":{"score":4,"rationale":"Statewide Medi-Cal implementation, federal-carrier guidance and CMS continuity rules indicate that the policy pattern can operate across large populations. Drug lists, risk criteria, contracts and monitoring must still be localized.","source_ids":["S4","S5","S6","S7"]}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"50K_TO_250K","scope":"A preregistered retrospective study of one medication class at one cooperating payer, linking authorization, pharmacy-claim and limited clinical-workflow data; includes privacy review, data engineering, clinical definitions, matched or difference-in-differences analysis, subgroup checks, targeted chart validation and reporting.","confidence":"MODERATE","assumptions":["Existing payer data contain authorization dates, paid and rejected claims, eligibility and prescriber identifiers.","One payer and one medication class are included.","Clinical review is limited to a stratified validation sample.","The band is a resource-equivalent estimate; no source reports a directly comparable study price."],"source_ids":["S1","S4","S5"]},"initial_deployment_startup":{"band_2026_usd":"250K_TO_1M","scope":"Configuration of one payer's existing pharmacy-authorization platform for one cohort, including eligibility and exception rules, data interfaces, privacy and legal review, clinical governance, notices, escalation, audit logging, testing, training, monitoring definitions and rollback capability.","confidence":"LOW","assumptions":["An existing authorization platform and pharmacy-claims feed can be modified rather than replaced.","No new enterprise-wide FHIR or pharmacy-benefit platform is built.","Rules require clinical, pharmacy, compliance, engineering, analytics and operations labor.","Official sources demonstrate feasibility and required functions but do not disclose comparable implementation costs."],"source_ids":["S4","S5","S6","S8"]},"operational_launch":{"band_2026_usd":"250K_TO_1M","scope":"Time-limited operation and separated evaluation for one cohort, including exception-review staffing, clinician escalation, patient and provider support, data-quality surveillance, safety and equity review, utilization and fiscal analysis, governance meetings and rollback readiness.","confidence":"LOW","assumptions":["Launch remains limited to one payer and medication class.","Monitoring is more intensive than routine benefit administration.","Serious or ambiguous cases receive manual clinical review.","The estimate includes evaluation and coordination but excludes expansion to additional payers or classes."],"source_ids":["S4","S6","S7"]},"annual_recurring":{"band_2026_usd":"250K_TO_1M","scope":"Ongoing operation for one established cohort, including rules and formulary maintenance, exception review, appeals support, audit sampling, safety and equity surveillance, utilization and fiscal reporting, compliance review, software maintenance and periodic policy reapproval.","confidence":"LOW","assumptions":["One cohort is maintained with continued protected-outcome surveillance.","Exception and escalation volumes remain manageable.","Annual utilization-management governance is retained.","No direct recurring-cost source exists; the band is a labor-and-system resource equivalent."],"source_ids":["S4","S6","S7"]}},"verified_pipeline_gates":{"externally_supported_problem":{"status":"YES","reason":"Primary research supports delays and discontinuation when authorization is imposed on established medication users, with independent patient and physician burden evidence. Exact renewal-specific prevalence is still a measurement gap.","source_ids":["S1","S2","S3"]},"externally_credible_adopter_or_authorizer":{"status":"YES","reason":"DHCS implemented automatic extensions, OPM issued carrier guidance and CMS regulates authorization continuity and utilization-management governance.","source_ids":["S4","S6","S7"]},"distinct_testable_incremental_claim":{"status":"NO","reason":"The core selective auto-renewal mechanism is already documented. The candidate does not yet specify a trigger set or comparator sufficiently distinct from Medi-Cal's extended-duration policy and OPM's chronic-condition, regular-fill and safety-exclusion criteria.","source_ids":["S4","S5","S6"]},"bounded_next_evidence_step":{"status":"YES","reason":"A one-payer, one-class retrospective natural-experiment analysis can compare existing automatic extension with ordinary renewal without exposing patients to a new policy.","source_ids":["S1","S4","S5"]},"no_unresolved_safety_or_authority_stop":{"status":"YES","reason":"The next step is records-based and noninterventional. Any later policy change remains conditional on accountable payer authority, exception-trigger validation, appeals, monitoring and rollback.","source_ids":["S4","S6","S7"]},"credible_cost_scope_and_range":{"status":"YES","reason":"The bands cover the material functions evidenced by implemented programs and regulatory guidance—claims and authorization data, clinical rules, platform configuration, notices, review, governance, monitoring, compliance and evaluation—while acknowledging that comparable direct cost data were not found.","source_ids":["S4","S5","S6","S7","S8"]}},"next_evidence_step":"Preregister a retrospective natural-experiment study within one payer and one maintenance-medication class already containing both automatically extended and ordinarily renewed authorizations. Compare matched stable, previously approved patients at expiration on 30-day authorization-attributable dispensing gaps, discontinuation, rejected claims, repeated document requests and staff touches; separately measure how often full renewal changes treatment or eligibility and whether the proposed exception triggers would have detected those cases. Use blinded chart review for a stratified sample and prespecified subgroup and missing-data analyses. Do not advance to a new live policy if automatic extension does not materially reduce attributable disruption, or if the trigger set misses clinically or eligibility-relevant review findings beyond a prespecified margin. S1 provides a methodological analogue; S4-S6 identify existing policy cohorts.","blocking_evidence":["Renewal-expiration-specific incidence and attributable disruption remain unmeasured; S1 concerns newly imposed authorization rather than routine expiration.","No comparative outcome evaluation of Medi-Cal's automatic extensions or FEHB carrier implementations was found in S1-S8.","The yield of full renewal review in apparently stable cases and the sensitivity of material-change triggers are unknown.","Therapy-specific safety, misuse, nonresponse, eligibility and clinical-monitoring requirements are not operationalized.","Equity, utilization, fiscal and displaced-workload effects of selective renewal are unverified.","Current payer contracts, notices, appeal processes and pharmacy-system capabilities must be confirmed for the selected cohort.","Direct comparable implementation and recurring-cost evidence was not found."] ,"research_disposition":"KNOWN_PRACTICE_DIFFUSION","world_novelty_boundary":"This bounded search found close implemented and officially recommended analogues, so the core mechanism should be treated as established practice rather than novel. The search does not establish worldwide prevalence or exhaust every payer, jurisdiction, patent, product or unpublished implementation. Any remaining claim is limited to the comparative performance of a newly operationalized trigger and monitoring design, not world novelty."}